DOT Price Prediction Summary • Short-term target (1 week): $1.33-$1.37 • Medium-term forecast (1 month): $1.24-$1.61 range • Bullish breakout level: $1.37 • CriticalDOT Price Prediction Summary • Short-term target (1 week): $1.33-$1.37 • Medium-term forecast (1 month): $1.24-$1.61 range • Bullish breakout level: $1.37 • Critical

DOT Price Prediction: Polkadot Eyes $1.37 Breakout Despite Oversold Conditions

2026/02/10 14:18
4 min read

DOT Price Prediction: Polkadot Eyes $1.37 Breakout Despite Oversold Conditions

Iris Coleman Feb 10, 2026 06:18

DOT Price Prediction Summary • Short-term target (1 week): $1.33-$1.37 • Medium-term forecast (1 month): $1.24-$1.61 range • Bullish breakout level: $1.37 • Critical support: $1.24...

DOT Price Prediction: Polkadot Eyes $1.37 Breakout Despite Oversold Conditions

DOT Price Prediction Summary

Short-term target (1 week): $1.33-$1.37 • Medium-term forecast (1 month): $1.24-$1.61 range • Bullish breakout level: $1.37 • Critical support: $1.24

What Crypto Analysts Are Saying About Polkadot

While specific analyst predictions from major KOLs are limited in recent days, historical analysis from blockchain.news contributors provides context for current market conditions. In January 2026, analysts including Alvin Lang, Iris Coleman, and Darius Baruo had projected DOT targets of $2.48-$3.30, significantly above current levels.

According to on-chain data from major exchanges, DOT has experienced substantial selling pressure, with the token trading well below previous analyst expectations. Current technical indicators suggest the market is testing key support levels that could determine the next directional move.

DOT Technical Analysis Breakdown

The DOT price prediction becomes clearer when examining current technical indicators. Polkadot is trading at $1.29, down 2.27% in the past 24 hours, with a trading range between $1.34 and $1.28.

The RSI reading of 27.92 places DOT firmly in oversold territory, typically indicating potential for a technical bounce. However, the MACD histogram at 0.0000 with both MACD and signal lines at -0.1801 suggests bearish momentum remains intact.

Polkadot's position relative to Bollinger Bands shows the token at 0.1723, meaning it's trading much closer to the lower band ($1.13) than the upper band ($2.08). This positioning near the lower band often precedes either a bounce or a breakdown below key support.

The moving average structure reveals the extent of the downtrend, with DOT trading below all major averages: SMA 7 ($1.34), SMA 20 ($1.61), SMA 50 ($1.85), and SMA 200 ($2.95). The exponential moving averages (EMA 12 at $1.45 and EMA 26 at $1.63) also serve as resistance levels.

Polkadot Price Targets: Bull vs Bear Case

Bullish Scenario

The Polkadot forecast for bulls focuses on the oversold RSI condition as a catalyst for recovery. Immediate resistance sits at $1.33, followed by stronger resistance at $1.37. A successful break above $1.37 could target the SMA 7 at $1.34, though this creates a compressed resistance zone.

If buying momentum emerges, the next significant target would be the EMA 12 at $1.45, representing a 12% gain from current levels. Beyond that, the pivotal SMA 20 at $1.61 becomes the medium-term objective, though this would require sustained buying pressure and broader crypto market support.

Bearish Scenario

The bear case for this DOT price prediction centers on the breakdown below immediate support at $1.27. If this level fails, strong support at $1.24 becomes critical. A break below $1.24 could accelerate selling toward the Bollinger Band lower bound at $1.13, representing a 12% decline.

The bearish momentum indicated by the MACD, combined with all moving averages acting as resistance, suggests any rallies may face selling pressure. Volume data showing $6.9 million in 24-hour trading suggests limited buying interest at current levels.

Should You Buy DOT? Entry Strategy

For traders considering DOT positions, the current oversold condition presents both opportunity and risk. Conservative buyers might wait for a break above $1.33 with volume confirmation before entering, using $1.27 as a stop-loss level.

More aggressive traders could consider accumulating near current levels ($1.29) with a tight stop below $1.24. This approach offers a favorable risk-reward ratio if the oversold bounce materializes.

The daily ATR of $0.14 suggests significant volatility, making position sizing crucial. Given the bearish overall structure, any long positions should be considered short-term trades rather than investments until DOT can reclaim key moving averages.

Conclusion

This DOT price prediction suggests Polkadot is at a critical juncture. While oversold conditions typically precede bounces, the broader bearish structure cannot be ignored. The most likely scenario involves a test of $1.33-$1.37 resistance, with the outcome determining whether DOT can begin a more substantial recovery or faces further downside toward $1.24.

The Polkadot forecast remains cautiously optimistic for short-term traders willing to manage risk carefully, though longer-term investors may want to wait for clearer bullish signals above key moving averages.

Disclaimer: Cryptocurrency price predictions are inherently speculative and should not be considered financial advice. Always conduct your own research and never invest more than you can afford to lose.

Image source: Shutterstock
  • dot price analysis
  • dot price prediction
Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.000539
$0.000539$0.000539
+15.09%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26